Kyoung-Mee Kim Selected Research

Disease Progression

1/2020	First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients.
12/2013	Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kyoung-Mee Kim Research Topics

Disease

146	Neoplasms (Cancer) 04/2024 - 02/2005
106	Stomach Neoplasms (Stomach Cancer) 05/2024 - 01/2008
30	Microsatellite Instability 01/2023 - 01/2002
21	Carcinoma (Carcinomatosis) 01/2024 - 02/2005
19	Adenocarcinoma 02/2024 - 09/2005
19	Colorectal Neoplasms (Colorectal Cancer) 01/2023 - 02/2002
10	Carcinogenesis 03/2023 - 01/2006
9	Lymphatic Metastasis 03/2023 - 12/2008
9	Neoplasm Metastasis (Metastasis) 01/2021 - 12/2009
8	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 09/2016 - 11/2006
6	Breast Neoplasms (Breast Cancer) 05/2013 - 08/2006
5	Adenoma (Adenomas) 01/2018 - 02/2005
4	Hypoxia (Hypoxemia) 03/2023 - 02/2016
4	Ascites 01/2018 - 01/2013
3	Ataxia Telangiectasia (Louis Bar Syndrome) 01/2022 - 10/2012
3	Turcot syndrome 10/2021 - 09/2017
3	Sarcopenia 03/2021 - 11/2020
3	Lymphoma (Lymphomas) 01/2021 - 01/2008
3	Polyps 01/2012 - 05/2010
3	Mucinous Adenocarcinoma (Mucinous Carcinoma) 08/2011 - 12/2008
3	B-Cell Lymphoma (Lymphoma, B Cell) 02/2009 - 01/2006
3	Marginal Zone B-Cell Lymphoma (MALT Lymphoma) 02/2009 - 01/2006
2	Melanoma (Melanoma, Malignant) 01/2021 - 08/2013
2	Adenocarcinoma of Lung 06/2020 - 01/2016
2	Disease Progression 01/2020 - 12/2013
2	Signet Ring Cell Carcinoma 05/2018 - 12/2008
2	Colonic Neoplasms (Colon Cancer) 01/2018 - 01/2017
2	Necrosis 06/2017 - 06/2010
2	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 03/2017 - 11/2015

Drug/Important Bio-Agent (IBA)

39	Biomarkers (Surrogate Marker)IBA 04/2024 - 08/2009
23	Proteins (Proteins, Gene)FDA Link 01/2024 - 01/2008
15	B7-H1 AntigenIBA 04/2024 - 01/2016
14	Immune Checkpoint InhibitorsIBA 09/2023 - 01/2018
13	ParaffinIBA 01/2023 - 01/2008
12	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 02/2005
11	RNA (Ribonucleic Acid)IBA 01/2023 - 02/2017
10	Formaldehyde (Formol)FDA Link 01/2023 - 01/2012
10	Phosphotransferases (Kinase)IBA 01/2022 - 06/2011
8	pembrolizumabIBA 02/2024 - 01/2018
8	Capecitabine (Xeloda)FDA Link 12/2018 - 07/2011
6	Messenger RNA (mRNA)IBA 01/2024 - 01/2012
6	AntibodiesIBA 01/2021 - 04/2012
6	Monoclonal AntibodiesIBA 01/2019 - 12/2013
6	Calcibiotic Root Canal SealerIBA 03/2017 - 02/2002
6	Imatinib Mesylate (Gleevec)FDA Link 10/2013 - 06/2008
5	PlatinumIBA 02/2024 - 01/2012
5	NucleotidesIBA 01/2021 - 07/2002
5	Cell-Free Nucleic AcidsIBA 01/2020 - 11/2015
5	Cisplatin (Platino)FDA LinkGeneric 12/2018 - 06/2010
5	Trastuzumab (Herceptin)FDA Link 03/2015 - 05/2013
4	Fluorouracil (Carac)FDA LinkGeneric 05/2024 - 01/2008
4	human ERBB2 proteinIBA 01/2022 - 12/2014
4	Small Interfering RNA (siRNA)IBA 12/2019 - 12/2011
4	S100 Proteins (S 100 Protein)IBA 09/2016 - 11/2006
4	Everolimus FDA Link 01/2016 - 07/2011
4	MucinsIBA 01/2013 - 09/2005
4	Cyclin D1IBA 08/2009 - 01/2008
3	NivolumabIBA 04/2024 - 06/2020
3	RamucirumabIBA 02/2024 - 01/2019
3	Type 2 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 2)IBA 11/2023 - 01/2016
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 03/2023 - 08/2009
3	LigandsIBA 09/2022 - 02/2017
3	MicroRNAs (MicroRNA)IBA 01/2021 - 01/2018
3	EnzymesIBA 01/2021 - 01/2013
3	Paclitaxel (Taxol)FDA LinkGeneric 01/2021 - 12/2014
3	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 01/2021 - 08/2015
3	Simvastatin (Zocor)FDA LinkGeneric 03/2020 - 06/2014
3	Leucovorin (Folinic Acid)FDA Link 01/2020 - 01/2008
3	1- (1- (imidazo(1,2- a)pyridin- 6- yl)ethyl)- 6- (1- methyl- 1H- pyrazol- 4- yl)- 1H- (1,2,3)triazolo(4,5- b)pyrazineIBA 01/2020 - 04/2019
3	Sorafenib (BAY 43-9006)FDA Link 01/2018 - 01/2017
3	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 12/2017 - 04/2015
3	Anaplastic Lymphoma KinaseIBA 01/2016 - 05/2013
3	tyrosine receptor (receptor, tyrosine)IBA 12/2015 - 05/2013
3	Cyclin-Dependent Kinase Inhibitor p16IBA 02/2009 - 01/2006
2	ErbB Receptors (EGF Receptor)IBA 04/2024 - 03/2016
2	delta proteinIBA 03/2023 - 01/2019
2	Fibroblast Growth Factors (Fibroblast Growth Factor)IBA 09/2022 - 01/2022
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 09/2022 - 06/2020
2	TensinsIBA 09/2022 - 06/2020
2	PTEN Phosphohydrolase (PTEN Phosphatase)IBA 09/2022 - 06/2020
2	ceralasertibIBA 01/2022 - 01/2021
2	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 01/2020 - 03/2019
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 03/2019 - 05/2013
2	Neutralizing AntibodiesIBA 01/2019 - 01/2015
2	Indicators and Reagents (Reagents)IBA 01/2018 - 02/2014
2	Lactic Acid (Lactate)FDA LinkGeneric 01/2018 - 07/2016
2	c-Mer Tyrosine KinaseIBA 12/2017 - 11/2017
2	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 08/2017 - 01/2016

Therapy/Procedure

38	Therapeutics 01/2021 - 01/2008
27	Drug Therapy (Chemotherapy) 04/2024 - 08/2006
21	Immunotherapy 01/2023 - 02/2016
19	Gastrectomy 12/2021 - 04/2008
9	Adjuvant Chemotherapy 10/2020 - 08/2006
8	Radiotherapy 01/2021 - 01/2012
6	Chemoradiotherapy 04/2020 - 01/2012
6	Adjuvant Chemoradiotherapy 04/2020 - 10/2015
5	Lymph Node Excision (Lymph Node Dissection) 01/2021 - 01/2012
4	Precision Medicine 02/2024 - 06/2011
3	Aftercare (After-Treatment) 01/2016 - 08/2009
3	Surgical Instruments (Clip) 10/2014 - 01/2011